antigen-1 in experimental autoimmune uveoretinitis.
Methods: B10.RIII mice were immunized with interphotoreceptor retinoid binding protein (IRBP) peptide 161-180 in complete Freund's adjuvant together with pertussis toxin. To investigate the involvement of VLA-4 and LFA-1 in EAU, expression of these molecules in the retina of EAU-developing mice was evaluated by immunohistochemistry. To examine whether EAU can be inhibited by blocking of these molecules, anti-VLA-4, anti-LFA-1 or control antibody (Ab) was intraperitoneally injected every other day from 5 and 13 days after immunization (effector phase).
Fourteen days and 28 days after immunization, the eyes and spleens were harvested.
The eyes were used for histologic analysis and cytokine mRNA expression analysis.
The spleens were used for Ag-recall cytokine production assays and intracellular cytokine assays. 
Conclusion:
VLA-4 and LFA-1 appear to play a significant role in the development of EAU during the effector phase. Treatment with Abs specific for these molecules can be a therapeutic candidate for patients with uveitis, however, Ab treatment is needed to be continued.
